Product is added to your Wishlist
Global Precision Medicine Market

Global Precision Medicine Market –Analysis and Forecast (2017-2026) (Focus on Ecosystem Player, Technology, Therapeutic Applications, Patent Landscape, Country Analysis, R&D Pipeline, Product Mapping, Market Share Analysis and Competitive Insights)

The global precision medicine market was dominated by the oncology segment in 2016. The oncology market is expected to grow with a CAGR of 10.4% from 2017 to 2026. The rise in the number of cancer cases has significantly increased the global economic burden and is estimated to be approximately $4 trillion in 2025.

SKU: BH002B
Published Year: 2017
 
 

Various advancements in the life sciences industry have paved the way for development of several precision medicine solutions. It is one of the most modernized trends in the healthcare industry that has projected tremendous level of progress in the last few years. The completion of the Human Genome project in 2003 and the precision medicine initiative in 2015 provided a path of opportunity to introduce new scientific, medical, and business models in the precision medicine market. The sole idea behind the development of precision medicine solution is to provide targeted therapies to population based on their genomic structure. Therefore, the application of ‘omics’ (genomics, proteomics, transcriptomics) analysis is widely used in this market. The precision medicine market is a multibillion market which consists of innumerable companies involved in the research and development, manufacturing and commercialization of several novel drugs and diagnostic kits to boost the Precision Medicine workflow. 

Currently, the precision medicine market is gaining preference among the masses due to the growth of personal healthcare devices and integration of smart technologies in the healthcare system. In addition, increasing collaborations and partnerships between various ecosystem players are aiding in the robust growth of the precision medicine market. The growth in the precision medicine market is propelled by an increasing demand for personalized treatment, technological innovation and advancement (including Biomarker-based tests/kits, next gene sequencing, and precise imaging), government support and regulations, which consequently, have created a demand for the precision medicine solutions. Governmental regulations and standards are sustaining the growth and development of the precision medicine market. The primary aim of these regulations is to make precision medicines more adaptable and focused towards genetic diseases related to oncology, skin, respiratory, central nervous system, cardiovascular, and infectious diseases, among others. 

The purpose of this study is to gain a holistic view of the precision medicine market in terms of various influencing factors, such as recent trends, technological advancements, and role of various key stakeholders in the market. The scope of this report constitutes of an in-depth study of the global precision medicine market. The market has been segmented into ‘ecosystem players’ ‘technology’, ‘therapeutic applications’ and ‘region’. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the crucial parameters that must be taken into consideration before entering into the market.

The research report aims at answering various aspects of the global precision medicine market with the help of the key factors driving the market, restraints and challenges that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key ecosystem players and key strategies & developments taking place in this market. 

The research study considers the market share analysis for a comprehensive understanding of the global precision medicine market and assesses the factors governing the same. The supply chain analysis, Porter’s Five Force analysis, patent landscape, detailed product mapping and R&D analysis have been included in the report.
The market by region has been further sub-segmented in countries and in each sub-segments, key market trends, list of key players, and recent developments were listed.

The answers to the following key questions can be derived from this report:

•    How did the precision medicine market evolve and what is its scope in the future?
•    What is the approach followed in the development of precision medicine solutions?
•    What are the key areas of interest for the development of precision medicine?
•    What are the major market drivers, challenges and opportunities in the global precision medicine market?
•    What are the key initiatives and programs launched in the precision medicine market?
•    What are the key developmental strategies which are being implemented by the key players to stand out in this market? Among these strategies, which strategy is currently dominating the market?
•    What are the precision medicine solutions provided by the key companies? What are the key products in pipeline?
•    Who are the key players holding significant number of patents in the precision medicine market?
•    How is the Porter’s Five Forces affecting the industry attractiveness in the precision medicine market?
•    What is the role of different stakeholders in value chain for the precision medicine market?
•    What is the total addressable market (TAM), segmental addressable market (SAM) and the potential market opportunity of the global precision medicine market?
•    What is the market share of different leading segments and sub-segments of the market for the years 2017 and 2026?
•    How each of the segments of the global precision medicine market will grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2026?
•    Who are the key players dominating the global precision medicine market and what are their respective shares in the market?
•    Who are the key players dominating the precision medicine market, in different segments namely the ecosystem players, technologies, and therapeutic applications? 
•    What are the influencing factors that may affect the market share of the key players?
•    Who are the leading ecosystem players in the precision medicine market and what is their contribution to the market? What are the key drivers and challenges in each ecosystem player?
•    How the market has been segmented on the basis of technology? Which technology is leading and what is its share in the market? What are the key drivers and challenges in each technology?
•    How the market has been segmented on the basis of therapeutic application? Which therapeutic application is leading and what is its share in the market? What are the key drivers and challenges in each therapeutic application?
•    Which geographical location will contribute to the highest sales of precision medicine solutions and how regions have been further segmented into countries?
•    Who are the key players dominating the precision medicine market, in different regions namely North America, Europe, and Asia Pacific? What are the key drivers and challenges in each of the geographical regions?  
•    How many countries are covered in each geographical region? Which country is currently dominating the precision medicine market?
•    What are the key strengths, weaknesses, opportunities, and threat for each of the key players in the precision medicine market?

The key players which have been contributing significantly to the precision medicine market include Abbott Laboratories, Almac Group, Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, ASURAGEN, INC., bioMerieux SA, BRISTOL-MYERS SQUIBB COMPANY, CETICS Healthcare Technologies GmbH, Eli-Lilly and Company,  F. Hoffmann-La Roche AG, GE Healthcare, Gilead Sciences, Inc., GlaxoSmithKline, IBM Corporation, Illumina, Inc., Intomics A/S, JOHNSON & JOHNSON, Laboratory Corporation of America, Merck KGaA, Novartis AG, Pfizer, Inc., QIAGEN, Quest Diagnostics, Randox Laboratories, SANOFI, Teva Pharmaceuticals Limited, and Thermo Fisher Scientific, among others.

TABLE OF CONTENT
Executive Summary
1 Report Scope & Methodlogy
1.1 Scope of the Report
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 Data Triangulation
1.3.4 Key Data Points from Primary Sources
1.3.5 Key Data Points from Secondary Sources
1.3.6 Top-Down  Approach (Segmental Analysis)
1.3.7 Bottom-Up Approach (Segmental Analysis)
1.5 Assumptions and Limitations
2 Market Overview
2.1 Introduction
2.1 Precision Medicine Approach
2.1 Evolution of Precision Medicine Technology
2.1 Precision Medicine: Areas of Interest
2.1 Initiatives and Programs
3 Market Dynamics
3.1 Overview
3.2 Impact Analysis
3.3 Drivers
3.4 Restraints
3.5 Opportunities
4 Competitive Insights
4.1 Share of Key Development and  Strategies
4.2 Competitive Landscape of Some of the Key Players
4.3 Market Share Analysis
4.4 Industry Attractiveness
4.3.1 Definition of Suppliers and Buyers in Precision Medicine Market
4.3.2 Bargaining Power of Suppliers
4.3.3 Bargaining Power of Buyers
4.3.4 Threat of New Entrants
4.3.5 Threat of Substitute Products
4.3.6 Intensity of Competitive Rivalry
4.5 Supply Chain Analysis
5 Industry Insights
5.1 Patent Analysis
5.2 Legal Requirements and Regulations
5.3 Role of FDA in Advancing Precision Medicine
5.4 Regulatory Bodies in Precision Medicine
5.5 Consortiums in the Precision Medicine Market
5.6 Alliance/Associations in the Precision medicine Market
6 Global Precision Medicine Market, by Ecosystem Players
6.1 Overview
6.2 Pharmaceutical and Biotechnology Companies
6.2.1 Role of Pharmaceutical and Biotechnology Companies
6.2.2 Drug Development Process
6.2.3 Examples of Some Precision Medicine Drugs
6.2.4 Pharmaceutical and Biotechnology Companies: Drivers and challenges
6.2.5 Pharmaceutical and Biotechnology Companies: Recent Key Developments
6.3 Diagnostic Companies and Clinical Research Laboratories
6.3.1 Pharmaceutical and Biotechnology Companies: Drivers and challenges
6.3.2 Diagnostic Tests Benefits for Stakeholders
6.3.3 Pharmaceutical and Biotechnology Companies: Recent Key Developments
6.4 Healthcare IT/ Big Data Companies
6.4.1 Benefits of Big Data
6.4.2 Pharmaceutical and Biotechnology Companies: Drivers and challenges
6.4.3 Basic Ingredients Provide by Big Data for Precision Medicine
6.4.4 Big Data Companies: Recent Key Developments
7 Global Precision Medicine Market, by Technology
7.1 Overview
7.2 Role of Biomarker Based Test
7.3 Companion Diagnostics
7.3.1 Drug and Companion Diagnostics Development Process
7.3.2 Companion Diagnostics:Drivers and challenges
7.3.3 Companion Diagnostics: Recent Key Developments
7.4 Bioinformatics
7.5 Big Data Analytics
7.6 Gene Sequencing
7.6.1 Sequencing Technologies in Precision Medicine
7.6.2 Gene Sequencing:Drivers and challenges
7.6.3 Applications of Gene Sequencing
7.6.4 Gene Sequencing: Recent Key Developments
7.7 Pharmacogenomics
7.7.1 Clinical Applications of Pharmacogenomics Testing
7.7.2 Role of FDA in Pharmacogenomics
7.8 Molecular Diagnostics
7.9 Others
7.9.1 Consumer Genomics
7.9.2 3D Printing
7.9.3 Prosthetic Market
7.9.4 Human tissues Market
8 Global Precision Medicine Market, by Therapeutic Application
8.1 Overview
8.2 Oncology
8.2.1 Types of Cancer
8.2.2 Government Initiatives
8.2.3 Oncology:Drivers and challenges
8.2.4 Oncology: Recent Key Developments
8.3 Cardiovascular
8.4 Central Nervous System
8.5 Infectious Diseases
8.6 Immunology
8.7 Others
8.8 Recent Key Developments
9 Global Precision Medicine Market, by Region
9.1 Overview
9.2 Key Insights
9.3 North America
9.3.1 Market Scope
9.3.2 North America: Market Insights and Statistics
9.3.3 North America: by Country
9.3.4 North America: by Ecosystem Players
9.3.5 North America: by Technology
9.3.6 North America: by Therapeutic Applications
9.3.7 North America: Market Dynamics
9.3.8 Key Regulatory Bodies and Associations
9.3.9 The U.S.
9.3.9.1 The U.S.: by Ecosystem Players
9.3.9.2 The U.S.: by Technology
9.3.9.3 The U.S.: by Therapeutic Applications
9.3.10 Canada
9.3.7 Key Market Players in North America
9.3.8 North America: Recent Key Developments
9.4 Europe
9.4.1 Market Scope
9.4.2 Europe: Market Insights and Statistics
9.4.3 Europe: by Country
9.4.4 Europe: by Ecosystem Players
9.4.5 Europe: by Technology
9.4.6 Europe: by Therapeutic Applications
9.4.7 Europe: Market Dynamics
9.4.8 Germany
9.4.9 The U.K.
9.4.10 France
9.4.11 Italy
9.4.12 Spain
9.4.13 Rest of Europe
9.4.14 Key Market Players in Europe
9.4.15 Europe: Recent Key Developments
9.5 Asia Pacific
9.5.1 Market Scope
9.5.2 Asia Pacific: Market Insights and Statistics
9.5.3 Asia Pacific: by Country
9.5.4 Asia Pacific: by Ecosystem Players
9.5.5 Asia Pacific: by Technology
9.5.6 Asia Pacific: by Therapeutic Applications
9.5.7 Asia Pacific: Market Dynamics
9.5.8 China
9.5.9 Japan
9.5.10 India
9.5.11 Australia
9.5.12 Rest of Asia Pacific
9.5.13 Key Market Players in Asia Pacific
9.6 Rest of the World
9.6.1 Rest of the World: Market Insights and Statistics
9.6.2 Rest of the World: by Ecosystem Players
9.6.3 Rest of the World by Technology
9.6.4 Rest of the World: by Therapeutic Applications
9.6.5 Asia Pacific: Market Dynamics
9.6.6 Middle East
9.6.7 South America
9.6.8 Africa
9.6.9 Rest of the World: Recent Key Developments
10 Company Profiles
10.1 Abbott Laboratories
10.1.1 Overview
10.1.2 Product Portfolio
10.1.3 Financials
10.1.3.1 Finacial Summary
10.1.4 SWOT Analysis
10.2 Almac Group
10.2.1 Overview
10.2.2 Product Portfolio
10.2.3 Financials
10.2.3.1 Finacial Summary
10.2.4 SWOT Analysis
10.3 Amgen, Inc
10.3.1 Overview
10.3.2 Product Portfolio
10.3.3 Financials
10.3.3.1 Finacial Summary
10.3.4 SWOT Analysis
10.4 ANGLE plc
10.4.1 Overview
10.4.2 Financials
10.4.2.1 Finacial Summary
10.4.3 SWOT Analysis
10.5 Astellas Pharma, Inc
10.5.1 Overview
10.5.2 Product Portfolio
10.5.3 Financials
10.5.3.1 Finacial Summary
10.5.4 SWOT Analysis
10.6 AstraZeneca PLC
10.6.1 Overview
10.6.2 Product Portfolio
10.6.3 Financials
10.6.3.1 Finacial Summary
10.6.4 SWOT Analysis
10.7 ASURAGEN, INC.
10.7.1 Overview
10.7.2 Product Portfolio
10.7.3 Corporate Summary
10.7.4 SWOT Analysis
10.8 Bio-Rad Laboratories, Inc.
10.8.1 Overview
10.8.2 Product Portfolio
10.8.3 Financials
10.8.3.1 Finacial Summary
10.8.4 SWOT Analysis
10.9 bioMérieux SA
10.9.1 Overview
10.9.2 Financials
10.9.2.1 Finacial Summary
10.9.3 SWOT Analysis
10.10 BRISTOL-MYERS SQUIBB COMPANY
10.10.1 Overview
10.10.2 Product Portfolio
10.10.3 Financials
10.10.3.1 Finacial Summary
10.10.4 SWOT Analysis
10.11 CETICS Healthcare Technologies GmbH
10.11.1 Overview
10.11.2 Product Portfolio
10.11.3 Corporate Summary
10.11.4 SWOT Analysis
10.12 Danaher Corporation
10.12.1 Overview
10.12.2 Product Portfolio
10.12.3 Financials
10.12.3.1 Finacial Summary
10.12.4 SWOT Analysis
10.13 Eli Lilly and Company
10.13.1 Overview
10.13.2 Product Portfolio
10.13.3 Financials
10.13.3.1 Finacial Summary
10.13.4 SWOT Analysis
10.14 Epic Sciences, Inc.
10.14.1 Overview
10.14.2 Corporate Summary
10.14.3 SWOT Analysis
10.15 F.Hoffmann-La Roche AG
10.15.1 Overview
10.15.2 Product Portfolio
10.15.3 Financials
10.15.3.1 Finacial Summary
10.15.4 SWOT Analysis
10.16 GE Corporation
10.16.1 Overview
10.16.2 Product Portfolio
10.16.3 Financials
10.16.3.1 Finacial Summary
10.16.4 SWOT Analysis
10.17 Gilead Sciences, Inc.
10.17.1 Overview
10.17.2 Product Portfolio
10.17.3 Financials
10.17.3.1 Finacial Summary
10.17.4 SWOT Analysis
10.18 GlaxoSmithKline Plc
10.18.1 Overview
10.18.2 Product Portfolio
10.18.3 Financials
10.18.3.1 Finacial Summary
10.18.4 SWOT Analysis
10.19 IBM Corporation
10.19.1 Overview
10.19.2 Product Portfolio
10.19.3 Financials
10.19.3.1 Finacial Summary
10.19.4 SWOT Analysis
10.20 Illumina, Inc.
10.20.1 Overview
10.20.2 Product Portfolio
10.20.3 Financials
10.20.3.1 Finacial Summary
10.20.4 SWOT Analysis
10.21 Intomics A/S
10.21.1 Overview
10.21.2 Product Portfolio
10.21.3 Corporate Summary
10.21.4 SWOT Analysis
10.22 JOHNSON & JOHNSON
10.22.1 Overview
10.22.2 Product Portfolio
10.22.3 Financials
10.22.3.1 Finacial Summary
10.22.4 SWOT Analysis
10.23 Laboratory Corporation of America
10.23.1 Overview
10.23.2 Product Portfolio
10.23.3 Financials
10.23.3.1 Finacial Summary
10.23.4 SWOT Analysis
10.24 MDX Health, Inc.
10.24.1 Overview
10.24.2 Financials
10.24.2.1 Finacial Summary
10.24.3 SWOT Analysis
10.25 Menarini Silicon Biosystems, Inc.
10.25.1 Overview
10.25.2 Product Portfolio
10.25.3 Corporate Summary
10.25.4 SWOT Analysis
10.26  KGaA
10.26.1 Overview
10.26.2 Financials
10.26.2.1 Finacial Summary
10.26.3 SWOT Analysis
10.27 Myriad Genetics, Inc.
10.27.1 Overview
10.27.2 Product Portfolio
10.27.3 Financials
10.27.3.1 Finacial Summary
10.27.4 SWOT Analysis
10.28 Novartis AG
10.28.1 Overview
10.28.2 Product Portfolio
10.28.3 Financials
10.28.3.1 Finacial Summary
10.28.4 SWOT Analysis
10.29 Oracle
10.29.1 Overview
10.29.2 Product Portfolio
10.29.3 Financials
10.29.3.1 Finacial Summary
10.29.4 SWOT Analysis
10.30 Pacific Biosciences of California, Inc.
10.30.1 Overview
10.30.2 Corporate Summary
10.30.3 Product Portfolio
10.30.4 Financials
10.30.4.1 Finacial Summary
10.30.5 SWOT Analysis
10.31 Partek, Inc.
10.31.1 Overview
10.31.2 Corporate Summary
10.31.3 Product Portfolio
10.31.4 SWOT Analysis
10.32 Pfizer
10.32.1 Overview
10.32.2 Product Portfolio
10.32.3 Financials
10.32.3.1 Finacial Summary
10.32.4 SWOT Analysis
10.33 QIAGEN
10.33.1 Overview
10.33.2 Product Portfolio
10.33.3 Financials
10.33.3.1 Finacial Summary
10.34.4 SWOT Analysis
10.34 Quest Diagnostics
10.34.1 Overview
10.34.2 Product Portfolio
10.34.3 Financials
10.34.3.1 Finacial Summary
10.34.4 SWOT Analysis
10.35 Randox Laboratories
10.35.1 Overview
10.35.2 Product Portfolio
10.35.3 Corporate Summary
10.35.4 SWOT Analysis
10.36 SANOFI
10.36.1 Overview
10.36.2 Product Portfolio
10.36.3 Financials
10.36.3.1 Finacial Summary
10.36.4 SWOT Analysis
10.37 Sysmex Corporation
10.37.1 Overview
10.37.2 Product Portfolio
10.37.3 Financials
10.37.3.1 Finacial Summary
10.37.4 SWOT Analysis
10.38 Teva Pharmaceuticals Industries Limited.
10.38.1 Overview
10.38.2 Product Portfolio
10.38.3 Financials
10.38.3.1 Finacial Summary
10.38.4 SWOT Analysis
10.39 Thermo Fisher Scientific
10.39.1 Overview
10.39.2 Product Portfolio
10.39.3 Financials
10.39.3.1 Finacial Summary
10.39.4 SWOT Analysis
10.40 TROVAGENE, INC.
10.40.1 Overview
10.40.2 Product Portfolio
10.40.3 Financials
10.40.3.1 Finacial Summary
10.40.4 SWOT Analysis
10.41 Snapshot of Some Key Companies
10.41.1 AB-BIOTICS SA
10.41.2 ARIEL Precision Medicine, Inc.
10.41.3 CARIS LIFE Science
10.41.4 Continuous Precision Medicine
10.41.5 GUARDANT HEALTH, INC
10.41.6 INNVENTIS
10.41.7 Intel Corporation
10.41.8 Mapmygenome
10.41.9 New Medicine Partners
10.41.10 Pacific Edge Diagnostics USA LIMITED
10.41.11 PRECISION FOR MEDICINE
10.41.12 Precision Medicine Alliance
10.41.13 Takeda Pharmaceuticals Company Limited
List of Tables
1 Global Pharma & Biotech Companies Precision Medicine Market, by Therapeutic Application, ($Billion) 
2 Example of Some Precision Medicine  Drugs
3 Biotechnology and Pharmaceutical Companies- Recent Key Developments
4 Global Diagnostic Tool Companies Precision Medicine Market, by Therapeutic Application, ($Billion) 
5 Diagnostic Test  Companies- Recent Key Developments
6 Global Healthcare IT/ Big Data Companies Precision Medicine Market, by Therapeutic Application, ($Billion)  
7 Service Providers- Recent Developments
8 Global Precision Medicine Market Value, by Technology Types ($Billion)
9 List of Biobanking Initiatives Across Selected OECD Countries
10 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
11 Global Precision Medicine Market Value, by Region ($Billion)
12 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
13 Global Precision Medicine Market Value, by Region ($Billion)
14 Next Generation Sequencing- Recent Key Developments
15 List of Biobanks
16 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
17 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
18 Companion Diagnostics- Recent Key Developments
19 List of  FDA Approved Companion diagnostics
20 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
21 List of  Few FDA Approved Pharmacogenomics Biomarkers in Drug Labelling
22 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
23 List of Few Human Genetic Tests Approved by FDA
24 List of Few Microbial Tests Approved by FDA
25 Others Molecular Diagnostics : List of Human Genetic Tests
26 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
27 Global Precision Medicine Market Value, by Technology ($Billion)
28 Cancer Precision Medicine Drugs and Indications
29 Oncology- Recent Developments
30 Global Precision Medicine Market Value, by Technology ($Billion)
31 Cardiovascular Precision Medicine Drugs/Tests/ and Indications
32 Global Precision Medicine Market Value, by Technology ($Billion)
33 Central Nervous System Precision Medicine Drugs and Indications
34 Global Precision Medicine Market Value, by Technology ($Billion)
35 Infectious Diseases Precision Medicine Drugs and Indications
36 Global Precision Medicine Market Value, by Technology ($Billion)
37 Global Precision Medicine Market Value, by Technology ($Billion)
38 Other Diseases: Examples of Some Drugs
39 Recent Key Developments
40 North America Precision Medicine Market, by Technology ($Billion)
41 North America Precision Medicine Market, by Therapeutic  Application ($Billion)
42 Key Market Players in North America
43 North American Pharmacogenomics Market Recent Key Developments
44 Europe Precision Medicine Market, by Technology ($Billion)
45 Europe Precision Medicine Market, by Therapeutic  Application ($Billion)
46 Key Market Players in Europe
47 Europe: Recent Key Developments
48 Asia Pacific (APAC) Precision Medicine Market, by Technology ($Billion)
49 Asia Pacific (APAC) Precision Medicine Market, by Therapeutic Applications ($Billion)
50 Key Market Players in Asia Pacific
51 Rest of the World (RoW) Precision Medicine Market, by Technology ($Billion)
52 Rest of the World (RoW) Precision Medicine Market, by Therapeutic Application ($Billion)
53 Recent Key Developments
List of Figures
1 Ecosystem Players in Precision Medicine
2 Global Precision Medicine Market Value, by Ecosystem Players ($Billion)
3 Global Pharma & Biotech Companies Precision Medicine Market Value, by Region ($Billion)
4 Role Of Pharmaceuticals And Biotech Companies
5 Drug Development Process
6 Pharmaceutical Companies- Drivers and Challenges
7 Global Diagnostic Tool Companies Precision Medicine Market Value, by Region ($Billion)
8 Diagnostic Companies: Drivers and Challenges
9 Diagnostic Tests Benefits for Stakeholders
10 Global Healthcare IT / Big Data Companies Precision Medicine Market Value, by Region ($Billion)
11 Three Data Drivers of the U.S. Precision Medicine Market
12 Benefits of Big Data
13 Big Data Companies: Drivers and Challenges
14 Transformation of Medicine
15 Basic Ingredients Provided By Big Data for Precision Medicine
16 Key Players
17 Technologies in Precision Medicine
18 Functions of Biomarkers
19 Biomarker Services
20 Biomarkers-List of Biobanks
21 Biomarker Market Dynamics
22 Biomarkers-Recent Key Developments
23 Sequencing Technologies in Pharmacogenomics
24 Next Generation Sequencing: Drivers and Challenges
25 Sequencing Applications
26 Global Precision Medicine Market Value, by Region ($Billion)
27 Global Precision Medicine Market Value, by Region ($Billion)
28 Drug And Companion Diagnostics Development Process
29 Companion Diagnostics: Market Dynamics
30 Global Precision Medicine Market Value, by Region ($Billion)
31 Clinical Applications of Pharmacogenomics Testing
32 Mechanism of Action
33 Role of FDA in Pharmacogenomics
34 Global Precision Medicine Market Value, by Region ($Billion)
35 Types of Molecular Diagnostics Tests
36 Global Precision Medicine Market Value, by Region ($Billion)
37 Therapeutic Areas in Precision Medicine
38 Global Precision Medicine Market, by Application, 2016 and 2026 ($Million)
39 Global Precision Medicine Market Value, By Eco System Players ($Billion)
40 Global Precision Medicine Market Value, by Region ($Billion)
41 Types of Cancer
42 Government Initiatives
43 Cancer related Some Important Facts
44 Oncology: Market Dynamics
45 Global Precision Medicine Market Value, By Eco System Players ($Billion)
46 Global Precision Medicine Market Value, by Region ($Billion)
47 Global Precision Medicine Market Value, By Eco System Players ($Billion)
48 Global Precision Medicine Market Value, by Region ($Billion)
49 Global Precision Medicine Market Value, By Eco System Players ($Billion)
50 Global Precision Medicine Market Value, by Region ($Billion)
51 Global Precision Medicine Market Value, By Eco System Players ($Billion)
52 Global Precision Medicine Market Value, by Region ($Billion)
53 Global Precision Medicine Market Value, By Eco System Players ($Billion)
54 Global Precision Medicine Market Value, by Region ($Billion)
55 Global Precision Medicine Market Value, by Region ($Billion)
56 North America Precision Medicine Market, By Region, 2015-2022 ($BILLION)
57 North America Precision Medicine   Market, By Ecosystem Players, 2015-2022 ($BILLION)
58 North America Precision Medicine   Market, By Therapeutic Applications, 2015-2022 ($BILLION)
59 North America: Market Dynamics
60 Key regulatory Bodies and Associations
61 North America Precision Medicine Market, ($Billion)
62 North America Precision Medicine Market, by Ecosystem Players, ($Billion)
63 The U.S. Precision Medicine Market ($Billion)
64 The U.S. Precision Medicine Market, by Ecosystem Players ($Billion)
65 The U.S. Precision Medicine Market, by Technology ($Billion)
66 The U.S. Precision Medicine Market, by Therapeutic Applications ($Billion)
67 Objectives Of The Precision Medicine Initiative
68 Canada Precision Medicine Market ($Billion)
69 Canada: Market Dynamics
70 Europe Precision Medicine Market, ($Billion)
71 Europe Precision Medicine Market, by Region ($Billion)
72 Europe Precision Medicine Market, by Ecosystem Players ($Billion)
73 Europe Precision Medicine Market, by Technology ($Billion)
74 Europe Precision Medicine Market, by Therapeutic Applications ($Billion)
75 Europe: Market Dynamics
76 Asia-Pacific (APAC) Precision Medicine Market, ($Billion)
77 Asia Pacific (APAC) Precision Medicine Market, by Region ($Billion)
78 Asia Pacific (APAC) Precision Medicine Market, by Ecosystem Players, ($Billion)
79 Asia Pacific (APAC) Precision Medicine Market, by Technology ($Billion)
80 Asia Pacific (APAC) Precision Medicine Market, by Therapeutic Applications ($Billion)
81 Asia Pacific: Market Dynamics
82 China: Market Dynamics
83 India: Market Dynamics
84 Rest of the World (RoW) Precision Medicine Market, ($Billion)
85 Rest of the World (RoW)Precision Medicine Market, by Region ($Billion)
86 Rest of the World (RoW) Precision Medicine Market, by Ecosystem Players, ($Billion)
87 Rest of the World (RoW) Precision Medicine Market, by Technology ($Billion)
88 Rest of the World (RoW) Precision Medicine Market, by Therapeutic Applications ($Billion)
89 Middle East: Market Dynamics
90 Examples of some of the programs helping in the Growth of Precision Medicine Market
91 South America: Market Dynamics
92 Africa: Market Dynamics

In the year 2003 marks the completion of the Human Genome Project, a 13-year, $3 billion collaborative effort for the sequencing, and mapping of complete human genome. This project further enabled the scientists to research extensively on the gene variants to specific diseases, and develop targeted therapeutics depending on the genetic profile of an individual. The completion, consequently, created the platform for the development of precision medicine. Since its introduction in the early 21st century, the precision medicine market has shown promising growth. 

Precision medicine involves the detailed study on patient specific information to diagnose, and characterize the diseases. The concept of precision medicine is rapidly growing in the medical community through tremendous expansion in various advanced technologies such as next generation sequencing, molecular biomarker analysis, bioinformatics, and big data analytics, among others. Owing to such advanced technologies, precision medicine acquired immense potential to prevent, and treat various diseases such as cancer, cardiovascular, neurology, diabetes, and other diseases, which are burdening the present healthcare system.

Precision medicine holds immense potential to restructure the healthcare industry. It is an emerging approach which enables the investigation of various diseases by evaluating the genetic makeup of an individual subject, thereby, providing a tailored therapeutic treatment to each patient. By applying a deeper understanding of diseases with richer patient data, precise risk assessments, active monitoring, early detection and advanced analytics, precision medicine can help physicians tailor medicines in accordance to the needs of individual patients leading to better outcomes at potentially lower costs. 

The multi-faceted approach to patient care involved in the precision medicine allows healthcare providers to avoid adverse drug reactions, improve methods of administration, focus efforts on prevention and earlier intervention, increase treatment options, and most importantly, improve the quality of life. Furthermore, the key achievements in the scientific research and technological advancements have played a major role in enabling a new era of patient care, and treatment. The understanding of the molecular mechanisms of diseases is increasing significantly, which is allowing the scientists to develop novel drugs, targeted therapies, and various preventive strategies. Thus, a new form of healthcare has emerged as a possibility which is based on the genetic data of an individual, algorithms, gene sequencing, and precision tools.

The growth of the precision medicine market over the last few years have been monumental. The factors propelling the growth of the precision medicine market are increasing focus on targeted therapy by reducing trial and error medicine, growing demand of non-invasive testing procedures, reducing adverse drug reactions through pharmacogenomics testing, advancement of technology in understanding human biology & disease susceptibility, and shift in the significance of medicine from reaction to prevention, among others. However, several clinical, economical, ethical and regulatory conditions continue to challenge the growth of the market.

One of the major restraints to the growth of precision medicine market is the potential threat to personal data. Also, the interaction within genes, genes with various environmental factors, and within various environmental factors, can contribute to large sources of variations that are analytically complex to explain.

The global precision medicine market is expected to be $141.7 billion by 2026. The market growth is attributed to the adoption of early stage treatments, increased number of adverse drug reactions cases, prevalence of chronic diseases, and advancement in genetic science, among others. Technologies such as gene sequencing, companion diagnostics, pharmacogenomics, bioinformatics, and big data analytics are expected to drive the market growth during the forecast period. The countries such as Spain, Italy, Singapore, India, China, KSA, the U.A.E. and Brazil offer several untapped and unexplored opportunities for the growth of this market. 

The global precision medicine market was dominated by the oncology segment in 2016. The oncology market is expected to grow with a CAGR of 10.4% from 2017 to 2026. The rise in the number of cancer cases has significantly increased the global economic burden and is estimated to be approximately $4 trillion in 2025. Several developed countries such as the U.S., the U.K., Germany, France, and Canada, among others, have been making strenuous efforts to develop actionable measures to control the prevalence of cancer. Immunology is expected to be the segment growing at the highest CAGR and the market is expected to be $11.27 billion in 2026. The prime reasons for this high growth are increasing cases of hypersensitivity, allergy, and immunodeficiency.

The market was dominated by the companion diagnostics segment in 2016 and is expected to grow at a CAGR of 11.56% from 2017 to 2026. Currently, significant research is being carried out by the key companies for advancing technologies such as big data analytics, and bioinformatics. According to a report cited by Oracle Health Sciences, the venture funding for precision medicine software in 2014 accounted for $268 million. Similarly, several biopharmaceutical companies are working extensively on the research and development of the targeted therapeutic drugs, tumor specific molecular biomarkers, companion diagnostics, and pharmacogenomics tests.

The global precision medicine market was dominated by the North America region in 2016. North America market is expected to grow with a CAGR of 9.66% from 2017 to 2026. The U.S. and Canada are the key contributors to the revenue generation in the North American precision medicine market. Moreover, with the announcement of Precision Medicine Initiative (PMI) project by the then U.S. president Barack Obama in 2015, the country has become a lucrative market for the investors. Asia Pacific region is expected to be the segment growing at the highest CAGR of 15.09% from 2017 to 2026. 

The emerging companies in the market are receiving substantial amount of investments from the conglomerate companies, venture capitalists, and government organizations, as a support for their ongoing research projects which are expected to disrupt the dynamics of the market when launched. The adoptability of a particular technology is entirely based on its clinical utility. Additionally, substantial investments are currently being made in bioinformatics, big data analytics start-ups, and service providing companies. The growing demand for genome mapping programs results into the generation of a large pool of genomic data. The major companies in the market are seeking the help of the bioinformatics, and big data/healthcare IT start-ups for handling such large pool of data which is the current market need. The service providing companies help in expanding the global reach of the major companies, and also play a significant role in increasing the adoptability of the sequencing technologies across the globe.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields
 

Various advancements in the life sciences industry have paved the way for development of several precision medicine solutions. It is one of the most modernized trends in the healthcare industry that has projected tremendous level of progress in the last few years. The completion of the Human Genome project in 2003 and the precision medicine initiative in 2015 provided a path of opportunity to introduce new scientific, medical, and business models in the precision medicine market. The sole idea behind the development of precision medicine solution is to provide targeted therapies to population based on their genomic structure. Therefore, the application of ‘omics’ (genomics, proteomics, transcriptomics) analysis is widely used in this market. The precision medicine market is a multibillion market which consists of innumerable companies involved in the research and development, manufacturing and commercialization of several novel drugs and diagnostic kits to boost the Precision Medicine workflow. 

Currently, the precision medicine market is gaining preference among the masses due to the growth of personal healthcare devices and integration of smart technologies in the healthcare system. In addition, increasing collaborations and partnerships between various ecosystem players are aiding in the robust growth of the precision medicine market. The growth in the precision medicine market is propelled by an increasing demand for personalized treatment, technological innovation and advancement (including Biomarker-based tests/kits, next gene sequencing, and precise imaging), government support and regulations, which consequently, have created a demand for the precision medicine solutions. Governmental regulations and standards are sustaining the growth and development of the precision medicine market. The primary aim of these regulations is to make precision medicines more adaptable and focused towards genetic diseases related to oncology, skin, respiratory, central nervous system, cardiovascular, and infectious diseases, among others. 

The purpose of this study is to gain a holistic view of the precision medicine market in terms of various influencing factors, such as recent trends, technological advancements, and role of various key stakeholders in the market. The scope of this report constitutes of an in-depth study of the global precision medicine market. The market has been segmented into ‘ecosystem players’ ‘technology’, ‘therapeutic applications’ and ‘region’. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the crucial parameters that must be taken into consideration before entering into the market.

The research report aims at answering various aspects of the global precision medicine market with the help of the key factors driving the market, restraints and challenges that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key ecosystem players and key strategies & developments taking place in this market. 

The research study considers the market share analysis for a comprehensive understanding of the global precision medicine market and assesses the factors governing the same. The supply chain analysis, Porter’s Five Force analysis, patent landscape, detailed product mapping and R&D analysis have been included in the report.
The market by region has been further sub-segmented in countries and in each sub-segments, key market trends, list of key players, and recent developments were listed.

The answers to the following key questions can be derived from this report:

•    How did the precision medicine market evolve and what is its scope in the future?
•    What is the approach followed in the development of precision medicine solutions?
•    What are the key areas of interest for the development of precision medicine?
•    What are the major market drivers, challenges and opportunities in the global precision medicine market?
•    What are the key initiatives and programs launched in the precision medicine market?
•    What are the key developmental strategies which are being implemented by the key players to stand out in this market? Among these strategies, which strategy is currently dominating the market?
•    What are the precision medicine solutions provided by the key companies? What are the key products in pipeline?
•    Who are the key players holding significant number of patents in the precision medicine market?
•    How is the Porter’s Five Forces affecting the industry attractiveness in the precision medicine market?
•    What is the role of different stakeholders in value chain for the precision medicine market?
•    What is the total addressable market (TAM), segmental addressable market (SAM) and the potential market opportunity of the global precision medicine market?
•    What is the market share of different leading segments and sub-segments of the market for the years 2017 and 2026?
•    How each of the segments of the global precision medicine market will grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2026?
•    Who are the key players dominating the global precision medicine market and what are their respective shares in the market?
•    Who are the key players dominating the precision medicine market, in different segments namely the ecosystem players, technologies, and therapeutic applications? 
•    What are the influencing factors that may affect the market share of the key players?
•    Who are the leading ecosystem players in the precision medicine market and what is their contribution to the market? What are the key drivers and challenges in each ecosystem player?
•    How the market has been segmented on the basis of technology? Which technology is leading and what is its share in the market? What are the key drivers and challenges in each technology?
•    How the market has been segmented on the basis of therapeutic application? Which therapeutic application is leading and what is its share in the market? What are the key drivers and challenges in each therapeutic application?
•    Which geographical location will contribute to the highest sales of precision medicine solutions and how regions have been further segmented into countries?
•    Who are the key players dominating the precision medicine market, in different regions namely North America, Europe, and Asia Pacific? What are the key drivers and challenges in each of the geographical regions?  
•    How many countries are covered in each geographical region? Which country is currently dominating the precision medicine market?
•    What are the key strengths, weaknesses, opportunities, and threat for each of the key players in the precision medicine market?

The key players which have been contributing significantly to the precision medicine market include Abbott Laboratories, Almac Group, Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, ASURAGEN, INC., bioMerieux SA, BRISTOL-MYERS SQUIBB COMPANY, CETICS Healthcare Technologies GmbH, Eli-Lilly and Company,  F. Hoffmann-La Roche AG, GE Healthcare, Gilead Sciences, Inc., GlaxoSmithKline, IBM Corporation, Illumina, Inc., Intomics A/S, JOHNSON & JOHNSON, Laboratory Corporation of America, Merck KGaA, Novartis AG, Pfizer, Inc., QIAGEN, Quest Diagnostics, Randox Laboratories, SANOFI, Teva Pharmaceuticals Limited, and Thermo Fisher Scientific, among others.

TABLE OF CONTENT
Executive Summary
1 Report Scope & Methodlogy
1.1 Scope of the Report
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 Data Triangulation
1.3.4 Key Data Points from Primary Sources
1.3.5 Key Data Points from Secondary Sources
1.3.6 Top-Down  Approach (Segmental Analysis)
1.3.7 Bottom-Up Approach (Segmental Analysis)
1.5 Assumptions and Limitations
2 Market Overview
2.1 Introduction
2.1 Precision Medicine Approach
2.1 Evolution of Precision Medicine Technology
2.1 Precision Medicine: Areas of Interest
2.1 Initiatives and Programs
3 Market Dynamics
3.1 Overview
3.2 Impact Analysis
3.3 Drivers
3.4 Restraints
3.5 Opportunities
4 Competitive Insights
4.1 Share of Key Development and  Strategies
4.2 Competitive Landscape of Some of the Key Players
4.3 Market Share Analysis
4.4 Industry Attractiveness
4.3.1 Definition of Suppliers and Buyers in Precision Medicine Market
4.3.2 Bargaining Power of Suppliers
4.3.3 Bargaining Power of Buyers
4.3.4 Threat of New Entrants
4.3.5 Threat of Substitute Products
4.3.6 Intensity of Competitive Rivalry
4.5 Supply Chain Analysis
5 Industry Insights
5.1 Patent Analysis
5.2 Legal Requirements and Regulations
5.3 Role of FDA in Advancing Precision Medicine
5.4 Regulatory Bodies in Precision Medicine
5.5 Consortiums in the Precision Medicine Market
5.6 Alliance/Associations in the Precision medicine Market
6 Global Precision Medicine Market, by Ecosystem Players
6.1 Overview
6.2 Pharmaceutical and Biotechnology Companies
6.2.1 Role of Pharmaceutical and Biotechnology Companies
6.2.2 Drug Development Process
6.2.3 Examples of Some Precision Medicine Drugs
6.2.4 Pharmaceutical and Biotechnology Companies: Drivers and challenges
6.2.5 Pharmaceutical and Biotechnology Companies: Recent Key Developments
6.3 Diagnostic Companies and Clinical Research Laboratories
6.3.1 Pharmaceutical and Biotechnology Companies: Drivers and challenges
6.3.2 Diagnostic Tests Benefits for Stakeholders
6.3.3 Pharmaceutical and Biotechnology Companies: Recent Key Developments
6.4 Healthcare IT/ Big Data Companies
6.4.1 Benefits of Big Data
6.4.2 Pharmaceutical and Biotechnology Companies: Drivers and challenges
6.4.3 Basic Ingredients Provide by Big Data for Precision Medicine
6.4.4 Big Data Companies: Recent Key Developments
7 Global Precision Medicine Market, by Technology
7.1 Overview
7.2 Role of Biomarker Based Test
7.3 Companion Diagnostics
7.3.1 Drug and Companion Diagnostics Development Process
7.3.2 Companion Diagnostics:Drivers and challenges
7.3.3 Companion Diagnostics: Recent Key Developments
7.4 Bioinformatics
7.5 Big Data Analytics
7.6 Gene Sequencing
7.6.1 Sequencing Technologies in Precision Medicine
7.6.2 Gene Sequencing:Drivers and challenges
7.6.3 Applications of Gene Sequencing
7.6.4 Gene Sequencing: Recent Key Developments
7.7 Pharmacogenomics
7.7.1 Clinical Applications of Pharmacogenomics Testing
7.7.2 Role of FDA in Pharmacogenomics
7.8 Molecular Diagnostics
7.9 Others
7.9.1 Consumer Genomics
7.9.2 3D Printing
7.9.3 Prosthetic Market
7.9.4 Human tissues Market
8 Global Precision Medicine Market, by Therapeutic Application
8.1 Overview
8.2 Oncology
8.2.1 Types of Cancer
8.2.2 Government Initiatives
8.2.3 Oncology:Drivers and challenges
8.2.4 Oncology: Recent Key Developments
8.3 Cardiovascular
8.4 Central Nervous System
8.5 Infectious Diseases
8.6 Immunology
8.7 Others
8.8 Recent Key Developments
9 Global Precision Medicine Market, by Region
9.1 Overview
9.2 Key Insights
9.3 North America
9.3.1 Market Scope
9.3.2 North America: Market Insights and Statistics
9.3.3 North America: by Country
9.3.4 North America: by Ecosystem Players
9.3.5 North America: by Technology
9.3.6 North America: by Therapeutic Applications
9.3.7 North America: Market Dynamics
9.3.8 Key Regulatory Bodies and Associations
9.3.9 The U.S.
9.3.9.1 The U.S.: by Ecosystem Players
9.3.9.2 The U.S.: by Technology
9.3.9.3 The U.S.: by Therapeutic Applications
9.3.10 Canada
9.3.7 Key Market Players in North America
9.3.8 North America: Recent Key Developments
9.4 Europe
9.4.1 Market Scope
9.4.2 Europe: Market Insights and Statistics
9.4.3 Europe: by Country
9.4.4 Europe: by Ecosystem Players
9.4.5 Europe: by Technology
9.4.6 Europe: by Therapeutic Applications
9.4.7 Europe: Market Dynamics
9.4.8 Germany
9.4.9 The U.K.
9.4.10 France
9.4.11 Italy
9.4.12 Spain
9.4.13 Rest of Europe
9.4.14 Key Market Players in Europe
9.4.15 Europe: Recent Key Developments
9.5 Asia Pacific
9.5.1 Market Scope
9.5.2 Asia Pacific: Market Insights and Statistics
9.5.3 Asia Pacific: by Country
9.5.4 Asia Pacific: by Ecosystem Players
9.5.5 Asia Pacific: by Technology
9.5.6 Asia Pacific: by Therapeutic Applications
9.5.7 Asia Pacific: Market Dynamics
9.5.8 China
9.5.9 Japan
9.5.10 India
9.5.11 Australia
9.5.12 Rest of Asia Pacific
9.5.13 Key Market Players in Asia Pacific
9.6 Rest of the World
9.6.1 Rest of the World: Market Insights and Statistics
9.6.2 Rest of the World: by Ecosystem Players
9.6.3 Rest of the World by Technology
9.6.4 Rest of the World: by Therapeutic Applications
9.6.5 Asia Pacific: Market Dynamics
9.6.6 Middle East
9.6.7 South America
9.6.8 Africa
9.6.9 Rest of the World: Recent Key Developments
10 Company Profiles
10.1 Abbott Laboratories
10.1.1 Overview
10.1.2 Product Portfolio
10.1.3 Financials
10.1.3.1 Finacial Summary
10.1.4 SWOT Analysis
10.2 Almac Group
10.2.1 Overview
10.2.2 Product Portfolio
10.2.3 Financials
10.2.3.1 Finacial Summary
10.2.4 SWOT Analysis
10.3 Amgen, Inc
10.3.1 Overview
10.3.2 Product Portfolio
10.3.3 Financials
10.3.3.1 Finacial Summary
10.3.4 SWOT Analysis
10.4 ANGLE plc
10.4.1 Overview
10.4.2 Financials
10.4.2.1 Finacial Summary
10.4.3 SWOT Analysis
10.5 Astellas Pharma, Inc
10.5.1 Overview
10.5.2 Product Portfolio
10.5.3 Financials
10.5.3.1 Finacial Summary
10.5.4 SWOT Analysis
10.6 AstraZeneca PLC
10.6.1 Overview
10.6.2 Product Portfolio
10.6.3 Financials
10.6.3.1 Finacial Summary
10.6.4 SWOT Analysis
10.7 ASURAGEN, INC.
10.7.1 Overview
10.7.2 Product Portfolio
10.7.3 Corporate Summary
10.7.4 SWOT Analysis
10.8 Bio-Rad Laboratories, Inc.
10.8.1 Overview
10.8.2 Product Portfolio
10.8.3 Financials
10.8.3.1 Finacial Summary
10.8.4 SWOT Analysis
10.9 bioMérieux SA
10.9.1 Overview
10.9.2 Financials
10.9.2.1 Finacial Summary
10.9.3 SWOT Analysis
10.10 BRISTOL-MYERS SQUIBB COMPANY
10.10.1 Overview
10.10.2 Product Portfolio
10.10.3 Financials
10.10.3.1 Finacial Summary
10.10.4 SWOT Analysis
10.11 CETICS Healthcare Technologies GmbH
10.11.1 Overview
10.11.2 Product Portfolio
10.11.3 Corporate Summary
10.11.4 SWOT Analysis
10.12 Danaher Corporation
10.12.1 Overview
10.12.2 Product Portfolio
10.12.3 Financials
10.12.3.1 Finacial Summary
10.12.4 SWOT Analysis
10.13 Eli Lilly and Company
10.13.1 Overview
10.13.2 Product Portfolio
10.13.3 Financials
10.13.3.1 Finacial Summary
10.13.4 SWOT Analysis
10.14 Epic Sciences, Inc.
10.14.1 Overview
10.14.2 Corporate Summary
10.14.3 SWOT Analysis
10.15 F.Hoffmann-La Roche AG
10.15.1 Overview
10.15.2 Product Portfolio
10.15.3 Financials
10.15.3.1 Finacial Summary
10.15.4 SWOT Analysis
10.16 GE Corporation
10.16.1 Overview
10.16.2 Product Portfolio
10.16.3 Financials
10.16.3.1 Finacial Summary
10.16.4 SWOT Analysis
10.17 Gilead Sciences, Inc.
10.17.1 Overview
10.17.2 Product Portfolio
10.17.3 Financials
10.17.3.1 Finacial Summary
10.17.4 SWOT Analysis
10.18 GlaxoSmithKline Plc
10.18.1 Overview
10.18.2 Product Portfolio
10.18.3 Financials
10.18.3.1 Finacial Summary
10.18.4 SWOT Analysis
10.19 IBM Corporation
10.19.1 Overview
10.19.2 Product Portfolio
10.19.3 Financials
10.19.3.1 Finacial Summary
10.19.4 SWOT Analysis
10.20 Illumina, Inc.
10.20.1 Overview
10.20.2 Product Portfolio
10.20.3 Financials
10.20.3.1 Finacial Summary
10.20.4 SWOT Analysis
10.21 Intomics A/S
10.21.1 Overview
10.21.2 Product Portfolio
10.21.3 Corporate Summary
10.21.4 SWOT Analysis
10.22 JOHNSON & JOHNSON
10.22.1 Overview
10.22.2 Product Portfolio
10.22.3 Financials
10.22.3.1 Finacial Summary
10.22.4 SWOT Analysis
10.23 Laboratory Corporation of America
10.23.1 Overview
10.23.2 Product Portfolio
10.23.3 Financials
10.23.3.1 Finacial Summary
10.23.4 SWOT Analysis
10.24 MDX Health, Inc.
10.24.1 Overview
10.24.2 Financials
10.24.2.1 Finacial Summary
10.24.3 SWOT Analysis
10.25 Menarini Silicon Biosystems, Inc.
10.25.1 Overview
10.25.2 Product Portfolio
10.25.3 Corporate Summary
10.25.4 SWOT Analysis
10.26  KGaA
10.26.1 Overview
10.26.2 Financials
10.26.2.1 Finacial Summary
10.26.3 SWOT Analysis
10.27 Myriad Genetics, Inc.
10.27.1 Overview
10.27.2 Product Portfolio
10.27.3 Financials
10.27.3.1 Finacial Summary
10.27.4 SWOT Analysis
10.28 Novartis AG
10.28.1 Overview
10.28.2 Product Portfolio
10.28.3 Financials
10.28.3.1 Finacial Summary
10.28.4 SWOT Analysis
10.29 Oracle
10.29.1 Overview
10.29.2 Product Portfolio
10.29.3 Financials
10.29.3.1 Finacial Summary
10.29.4 SWOT Analysis
10.30 Pacific Biosciences of California, Inc.
10.30.1 Overview
10.30.2 Corporate Summary
10.30.3 Product Portfolio
10.30.4 Financials
10.30.4.1 Finacial Summary
10.30.5 SWOT Analysis
10.31 Partek, Inc.
10.31.1 Overview
10.31.2 Corporate Summary
10.31.3 Product Portfolio
10.31.4 SWOT Analysis
10.32 Pfizer
10.32.1 Overview
10.32.2 Product Portfolio
10.32.3 Financials
10.32.3.1 Finacial Summary
10.32.4 SWOT Analysis
10.33 QIAGEN
10.33.1 Overview
10.33.2 Product Portfolio
10.33.3 Financials
10.33.3.1 Finacial Summary
10.34.4 SWOT Analysis
10.34 Quest Diagnostics
10.34.1 Overview
10.34.2 Product Portfolio
10.34.3 Financials
10.34.3.1 Finacial Summary
10.34.4 SWOT Analysis
10.35 Randox Laboratories
10.35.1 Overview
10.35.2 Product Portfolio
10.35.3 Corporate Summary
10.35.4 SWOT Analysis
10.36 SANOFI
10.36.1 Overview
10.36.2 Product Portfolio
10.36.3 Financials
10.36.3.1 Finacial Summary
10.36.4 SWOT Analysis
10.37 Sysmex Corporation
10.37.1 Overview
10.37.2 Product Portfolio
10.37.3 Financials
10.37.3.1 Finacial Summary
10.37.4 SWOT Analysis
10.38 Teva Pharmaceuticals Industries Limited.
10.38.1 Overview
10.38.2 Product Portfolio
10.38.3 Financials
10.38.3.1 Finacial Summary
10.38.4 SWOT Analysis
10.39 Thermo Fisher Scientific
10.39.1 Overview
10.39.2 Product Portfolio
10.39.3 Financials
10.39.3.1 Finacial Summary
10.39.4 SWOT Analysis
10.40 TROVAGENE, INC.
10.40.1 Overview
10.40.2 Product Portfolio
10.40.3 Financials
10.40.3.1 Finacial Summary
10.40.4 SWOT Analysis
10.41 Snapshot of Some Key Companies
10.41.1 AB-BIOTICS SA
10.41.2 ARIEL Precision Medicine, Inc.
10.41.3 CARIS LIFE Science
10.41.4 Continuous Precision Medicine
10.41.5 GUARDANT HEALTH, INC
10.41.6 INNVENTIS
10.41.7 Intel Corporation
10.41.8 Mapmygenome
10.41.9 New Medicine Partners
10.41.10 Pacific Edge Diagnostics USA LIMITED
10.41.11 PRECISION FOR MEDICINE
10.41.12 Precision Medicine Alliance
10.41.13 Takeda Pharmaceuticals Company Limited
List of Tables
1 Global Pharma & Biotech Companies Precision Medicine Market, by Therapeutic Application, ($Billion) 
2 Example of Some Precision Medicine  Drugs
3 Biotechnology and Pharmaceutical Companies- Recent Key Developments
4 Global Diagnostic Tool Companies Precision Medicine Market, by Therapeutic Application, ($Billion) 
5 Diagnostic Test  Companies- Recent Key Developments
6 Global Healthcare IT/ Big Data Companies Precision Medicine Market, by Therapeutic Application, ($Billion)  
7 Service Providers- Recent Developments
8 Global Precision Medicine Market Value, by Technology Types ($Billion)
9 List of Biobanking Initiatives Across Selected OECD Countries
10 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
11 Global Precision Medicine Market Value, by Region ($Billion)
12 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
13 Global Precision Medicine Market Value, by Region ($Billion)
14 Next Generation Sequencing- Recent Key Developments
15 List of Biobanks
16 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
17 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
18 Companion Diagnostics- Recent Key Developments
19 List of  FDA Approved Companion diagnostics
20 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
21 List of  Few FDA Approved Pharmacogenomics Biomarkers in Drug Labelling
22 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
23 List of Few Human Genetic Tests Approved by FDA
24 List of Few Microbial Tests Approved by FDA
25 Others Molecular Diagnostics : List of Human Genetic Tests
26 Global Precision Medicine Market Value, by Therapeutic Applications ($Billion)
27 Global Precision Medicine Market Value, by Technology ($Billion)
28 Cancer Precision Medicine Drugs and Indications
29 Oncology- Recent Developments
30 Global Precision Medicine Market Value, by Technology ($Billion)
31 Cardiovascular Precision Medicine Drugs/Tests/ and Indications
32 Global Precision Medicine Market Value, by Technology ($Billion)
33 Central Nervous System Precision Medicine Drugs and Indications
34 Global Precision Medicine Market Value, by Technology ($Billion)
35 Infectious Diseases Precision Medicine Drugs and Indications
36 Global Precision Medicine Market Value, by Technology ($Billion)
37 Global Precision Medicine Market Value, by Technology ($Billion)
38 Other Diseases: Examples of Some Drugs
39 Recent Key Developments
40 North America Precision Medicine Market, by Technology ($Billion)
41 North America Precision Medicine Market, by Therapeutic  Application ($Billion)
42 Key Market Players in North America
43 North American Pharmacogenomics Market Recent Key Developments
44 Europe Precision Medicine Market, by Technology ($Billion)
45 Europe Precision Medicine Market, by Therapeutic  Application ($Billion)
46 Key Market Players in Europe
47 Europe: Recent Key Developments
48 Asia Pacific (APAC) Precision Medicine Market, by Technology ($Billion)
49 Asia Pacific (APAC) Precision Medicine Market, by Therapeutic Applications ($Billion)
50 Key Market Players in Asia Pacific
51 Rest of the World (RoW) Precision Medicine Market, by Technology ($Billion)
52 Rest of the World (RoW) Precision Medicine Market, by Therapeutic Application ($Billion)
53 Recent Key Developments
List of Figures
1 Ecosystem Players in Precision Medicine
2 Global Precision Medicine Market Value, by Ecosystem Players ($Billion)
3 Global Pharma & Biotech Companies Precision Medicine Market Value, by Region ($Billion)
4 Role Of Pharmaceuticals And Biotech Companies
5 Drug Development Process
6 Pharmaceutical Companies- Drivers and Challenges
7 Global Diagnostic Tool Companies Precision Medicine Market Value, by Region ($Billion)
8 Diagnostic Companies: Drivers and Challenges
9 Diagnostic Tests Benefits for Stakeholders
10 Global Healthcare IT / Big Data Companies Precision Medicine Market Value, by Region ($Billion)
11 Three Data Drivers of the U.S. Precision Medicine Market
12 Benefits of Big Data
13 Big Data Companies: Drivers and Challenges
14 Transformation of Medicine
15 Basic Ingredients Provided By Big Data for Precision Medicine
16 Key Players
17 Technologies in Precision Medicine
18 Functions of Biomarkers
19 Biomarker Services
20 Biomarkers-List of Biobanks
21 Biomarker Market Dynamics
22 Biomarkers-Recent Key Developments
23 Sequencing Technologies in Pharmacogenomics
24 Next Generation Sequencing: Drivers and Challenges
25 Sequencing Applications
26 Global Precision Medicine Market Value, by Region ($Billion)
27 Global Precision Medicine Market Value, by Region ($Billion)
28 Drug And Companion Diagnostics Development Process
29 Companion Diagnostics: Market Dynamics
30 Global Precision Medicine Market Value, by Region ($Billion)
31 Clinical Applications of Pharmacogenomics Testing
32 Mechanism of Action
33 Role of FDA in Pharmacogenomics
34 Global Precision Medicine Market Value, by Region ($Billion)
35 Types of Molecular Diagnostics Tests
36 Global Precision Medicine Market Value, by Region ($Billion)
37 Therapeutic Areas in Precision Medicine
38 Global Precision Medicine Market, by Application, 2016 and 2026 ($Million)
39 Global Precision Medicine Market Value, By Eco System Players ($Billion)
40 Global Precision Medicine Market Value, by Region ($Billion)
41 Types of Cancer
42 Government Initiatives
43 Cancer related Some Important Facts
44 Oncology: Market Dynamics
45 Global Precision Medicine Market Value, By Eco System Players ($Billion)
46 Global Precision Medicine Market Value, by Region ($Billion)
47 Global Precision Medicine Market Value, By Eco System Players ($Billion)
48 Global Precision Medicine Market Value, by Region ($Billion)
49 Global Precision Medicine Market Value, By Eco System Players ($Billion)
50 Global Precision Medicine Market Value, by Region ($Billion)
51 Global Precision Medicine Market Value, By Eco System Players ($Billion)
52 Global Precision Medicine Market Value, by Region ($Billion)
53 Global Precision Medicine Market Value, By Eco System Players ($Billion)
54 Global Precision Medicine Market Value, by Region ($Billion)
55 Global Precision Medicine Market Value, by Region ($Billion)
56 North America Precision Medicine Market, By Region, 2015-2022 ($BILLION)
57 North America Precision Medicine   Market, By Ecosystem Players, 2015-2022 ($BILLION)
58 North America Precision Medicine   Market, By Therapeutic Applications, 2015-2022 ($BILLION)
59 North America: Market Dynamics
60 Key regulatory Bodies and Associations
61 North America Precision Medicine Market, ($Billion)
62 North America Precision Medicine Market, by Ecosystem Players, ($Billion)
63 The U.S. Precision Medicine Market ($Billion)
64 The U.S. Precision Medicine Market, by Ecosystem Players ($Billion)
65 The U.S. Precision Medicine Market, by Technology ($Billion)
66 The U.S. Precision Medicine Market, by Therapeutic Applications ($Billion)
67 Objectives Of The Precision Medicine Initiative
68 Canada Precision Medicine Market ($Billion)
69 Canada: Market Dynamics
70 Europe Precision Medicine Market, ($Billion)
71 Europe Precision Medicine Market, by Region ($Billion)
72 Europe Precision Medicine Market, by Ecosystem Players ($Billion)
73 Europe Precision Medicine Market, by Technology ($Billion)
74 Europe Precision Medicine Market, by Therapeutic Applications ($Billion)
75 Europe: Market Dynamics
76 Asia-Pacific (APAC) Precision Medicine Market, ($Billion)
77 Asia Pacific (APAC) Precision Medicine Market, by Region ($Billion)
78 Asia Pacific (APAC) Precision Medicine Market, by Ecosystem Players, ($Billion)
79 Asia Pacific (APAC) Precision Medicine Market, by Technology ($Billion)
80 Asia Pacific (APAC) Precision Medicine Market, by Therapeutic Applications ($Billion)
81 Asia Pacific: Market Dynamics
82 China: Market Dynamics
83 India: Market Dynamics
84 Rest of the World (RoW) Precision Medicine Market, ($Billion)
85 Rest of the World (RoW)Precision Medicine Market, by Region ($Billion)
86 Rest of the World (RoW) Precision Medicine Market, by Ecosystem Players, ($Billion)
87 Rest of the World (RoW) Precision Medicine Market, by Technology ($Billion)
88 Rest of the World (RoW) Precision Medicine Market, by Therapeutic Applications ($Billion)
89 Middle East: Market Dynamics
90 Examples of some of the programs helping in the Growth of Precision Medicine Market
91 South America: Market Dynamics
92 Africa: Market Dynamics

In the year 2003 marks the completion of the Human Genome Project, a 13-year, $3 billion collaborative effort for the sequencing, and mapping of complete human genome. This project further enabled the scientists to research extensively on the gene variants to specific diseases, and develop targeted therapeutics depending on the genetic profile of an individual. The completion, consequently, created the platform for the development of precision medicine. Since its introduction in the early 21st century, the precision medicine market has shown promising growth. 

Precision medicine involves the detailed study on patient specific information to diagnose, and characterize the diseases. The concept of precision medicine is rapidly growing in the medical community through tremendous expansion in various advanced technologies such as next generation sequencing, molecular biomarker analysis, bioinformatics, and big data analytics, among others. Owing to such advanced technologies, precision medicine acquired immense potential to prevent, and treat various diseases such as cancer, cardiovascular, neurology, diabetes, and other diseases, which are burdening the present healthcare system.

Precision medicine holds immense potential to restructure the healthcare industry. It is an emerging approach which enables the investigation of various diseases by evaluating the genetic makeup of an individual subject, thereby, providing a tailored therapeutic treatment to each patient. By applying a deeper understanding of diseases with richer patient data, precise risk assessments, active monitoring, early detection and advanced analytics, precision medicine can help physicians tailor medicines in accordance to the needs of individual patients leading to better outcomes at potentially lower costs. 

The multi-faceted approach to patient care involved in the precision medicine allows healthcare providers to avoid adverse drug reactions, improve methods of administration, focus efforts on prevention and earlier intervention, increase treatment options, and most importantly, improve the quality of life. Furthermore, the key achievements in the scientific research and technological advancements have played a major role in enabling a new era of patient care, and treatment. The understanding of the molecular mechanisms of diseases is increasing significantly, which is allowing the scientists to develop novel drugs, targeted therapies, and various preventive strategies. Thus, a new form of healthcare has emerged as a possibility which is based on the genetic data of an individual, algorithms, gene sequencing, and precision tools.

The growth of the precision medicine market over the last few years have been monumental. The factors propelling the growth of the precision medicine market are increasing focus on targeted therapy by reducing trial and error medicine, growing demand of non-invasive testing procedures, reducing adverse drug reactions through pharmacogenomics testing, advancement of technology in understanding human biology & disease susceptibility, and shift in the significance of medicine from reaction to prevention, among others. However, several clinical, economical, ethical and regulatory conditions continue to challenge the growth of the market.

One of the major restraints to the growth of precision medicine market is the potential threat to personal data. Also, the interaction within genes, genes with various environmental factors, and within various environmental factors, can contribute to large sources of variations that are analytically complex to explain.

The global precision medicine market is expected to be $141.7 billion by 2026. The market growth is attributed to the adoption of early stage treatments, increased number of adverse drug reactions cases, prevalence of chronic diseases, and advancement in genetic science, among others. Technologies such as gene sequencing, companion diagnostics, pharmacogenomics, bioinformatics, and big data analytics are expected to drive the market growth during the forecast period. The countries such as Spain, Italy, Singapore, India, China, KSA, the U.A.E. and Brazil offer several untapped and unexplored opportunities for the growth of this market. 

The global precision medicine market was dominated by the oncology segment in 2016. The oncology market is expected to grow with a CAGR of 10.4% from 2017 to 2026. The rise in the number of cancer cases has significantly increased the global economic burden and is estimated to be approximately $4 trillion in 2025. Several developed countries such as the U.S., the U.K., Germany, France, and Canada, among others, have been making strenuous efforts to develop actionable measures to control the prevalence of cancer. Immunology is expected to be the segment growing at the highest CAGR and the market is expected to be $11.27 billion in 2026. The prime reasons for this high growth are increasing cases of hypersensitivity, allergy, and immunodeficiency.

The market was dominated by the companion diagnostics segment in 2016 and is expected to grow at a CAGR of 11.56% from 2017 to 2026. Currently, significant research is being carried out by the key companies for advancing technologies such as big data analytics, and bioinformatics. According to a report cited by Oracle Health Sciences, the venture funding for precision medicine software in 2014 accounted for $268 million. Similarly, several biopharmaceutical companies are working extensively on the research and development of the targeted therapeutic drugs, tumor specific molecular biomarkers, companion diagnostics, and pharmacogenomics tests.

The global precision medicine market was dominated by the North America region in 2016. North America market is expected to grow with a CAGR of 9.66% from 2017 to 2026. The U.S. and Canada are the key contributors to the revenue generation in the North American precision medicine market. Moreover, with the announcement of Precision Medicine Initiative (PMI) project by the then U.S. president Barack Obama in 2015, the country has become a lucrative market for the investors. Asia Pacific region is expected to be the segment growing at the highest CAGR of 15.09% from 2017 to 2026. 

The emerging companies in the market are receiving substantial amount of investments from the conglomerate companies, venture capitalists, and government organizations, as a support for their ongoing research projects which are expected to disrupt the dynamics of the market when launched. The adoptability of a particular technology is entirely based on its clinical utility. Additionally, substantial investments are currently being made in bioinformatics, big data analytics start-ups, and service providing companies. The growing demand for genome mapping programs results into the generation of a large pool of genomic data. The major companies in the market are seeking the help of the bioinformatics, and big data/healthcare IT start-ups for handling such large pool of data which is the current market need. The service providing companies help in expanding the global reach of the major companies, and also play a significant role in increasing the adoptability of the sequencing technologies across the globe.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields

OUR HAPPY CLIENTS


related reports

 

OUR CLIENTS

Get yourself updated on key emerging technology markets

Know about our market intelligence coverage in key sectors